Source: https://www.federalregister.gov/documents/2013/05/16/2013-11602/government-owned-inventions-availability-for-licensing
Timestamp: 2018-04-20 17:28:07
Document Index: 231925982

Matched Legal Cases: ['Application No. 61', 'Application No. 61', 'Application No. 61', 'Application No. 61', 'Application No. 13', 'Application No. 13', 'Application No. 13']

https://www.federalregister.gov/d/2013-11602 https://www.federalregister.gov/d/2013-11602
May be useful in monitoring effectiveness of antiretroviral treatment
Intellectual Property: HHS Reference No. E-053-2013/0—US Application No. 61/784,763 filed 14 Mar 2013
Lower potential for replication
Decreased toxicity after purification
Intellectual Property: HHS Reference No. E-036-2013/0—US Application No. 61/759,516 filed 01 Feb 2013
Collaborative Research Opportunity: The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Start Printed Page 28858Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy. For collaboration opportunities, please contact Suzanne L. Winfield, Ph.D. at winfiels@mail.nih.gov or 301-402-4324.
T cells with enhanced proliferation, survival, and function.
Robust tumor response without the need of lymphodepletion and exogenous cytokine support.
Intellectual Property: HHS Reference No. E-272-2012/0—US Provisional Application No. 61/716,653 filed 22 Oct 2012
Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of microRNA-155 to enhance T cell-based immunotherapies. For collaboration opportunities, please contact Luca Gattinoni at gattinol@mail.nih.gov or 301-451-6914, or Nicholas Restifo at restifo@nih.gov or 301-496-4904.
Description of Technology: This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2).
Compounds are specific to one isoform of pyruvate kinase.
Compounds target tumor cells and not normal cells, so side effects may be reduced.
Compounds are small molecules which may be further optimized.
Intellectual Property: HHS Reference No. E-298-2011/1—US Provisional Application No. 61/752,698 filed 15 Jan 2013
HHS Reference No. E-326-2008/0—
US Patent Application No. 13/123,297 filed 25 Apr 2011
US Patent Application No. 13/433,656 filed 29 Mar 2012
Various international patent applications filed
HHS Reference No. E-120-2010/0—
US Patent Application No. 13/643,594 filed 26 Oct 2012